Lv1
30 积分 2022-07-13 加入
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
16小时前
待确认
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
1天前
已完结
An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202
3天前
已完结
Anlotinib in progressive RAI-refractory differentiated thyroid cancer: long-term results and PET/CT prognostic markers
3个月前
已完结
皖公网安备34019202002308
